Real GOCOVRI® experiences

In these videos, you will see real patients describe how they live with dyskinesia and OFF time and how GOCOVRI® made a difference in their lives.

Watch Real patients talk about their experiences living with dyskinesia

Watch Laura’s story

Diagnosed with dyskinesia in 2010, 3 years after her PD diagnosis, Laura won’t let dyskinesia and OFF time keep her from living an active lifestyle. Not ready to commit to surgery, she turned to GOCOVRI®. Now she can keep more of a routine and get back to her beloved horses.

Watch Ervin’s story

Ervin enjoys giving back to the community, but when he started experiencing dyskinesia in 2014, 11 years after his PD diagnosis, he worried he would have to take a step back from helping others. With GOCOVRI®, Ervin has more control of his dyskinesia and OFF time. Now, he and his wife, Gayle, continue to stay engaged in local support groups.

Please visit again for new stories from real Patients, Care Partners, and HEALTHCARE PROFESSIONALS who share their GOCOVRI® experiences.

Individual treatment experiences may vary.

INDICATION and important safety information

GOCOVRI® (amantadine) extended release capsules is indicated:

  • For the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications
  • As adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease experiencing “off” episodes

It is not known if GOCOVRI is safe and effective in children.


GOCOVRI is contraindicated in patients with creatinine clearance below 15 mL/min/1.73 m2.


Falling Asleep During Activities of Daily Living and Somnolence: Patients treated with Parkinson’s disease medications have reported falling asleep during activities of daily living. If a patient develops daytime sleepiness during activities that require full attention (e.g., driving a motor vehicle, conversations, eating), GOCOVRI should ordinarily be discontinued or the patient should be advised to avoid potentially dangerous activities.

Suicidality and Depression: Monitor patients for depression, including suicidal ideation or behavior. Prescribers should consider whether the benefits outweigh the risks of treatment with GOCOVRI in patients with a history of suicidality or depression.

Hallucinations/Psychotic Behavior: Patients with a major psychotic disorder should ordinarily not be treated with GOCOVRI because of the risk of exacerbating psychosis. Observe patients for the occurrence of hallucinations throughout treatment, especially at initiation and after dose increases.

Dizziness and Orthostatic Hypotension: Monitor patients for dizziness and orthostatic hypotension, especially after starting GOCOVRI or increasing the dose.

Withdrawal-Emergent Hyperpyrexia and Confusion: Rapid dose reduction or abrupt discontinuation of GOCOVRI, may cause an increase in the symptoms of Parkinson’s disease or cause delirium, agitation, delusions, hallucinations, paranoid reaction, stupor, anxiety, depression, or slurred speech. Avoid sudden discontinuation of GOCOVRI.

Impulse Control/Compulsive Behaviors: Patients may experience urges (e.g. gambling, sexual, money spending, binge eating) and the inability to control them. It is important for prescribers to ask patients or their caregivers about the development of new or increased urges. Consider dose reduction or stopping medications.

The most common adverse reactions (>10%) were hallucination, dizziness, dry mouth, peripheral edema, constipation, fall, and orthostatic hypotension.

View the full Prescribing Information.